Publications in collaboration with researchers from Guy's Hospital (11)

2024

  1. Approach to Mycosis Fungoides in children: Consensus-based recommendations

    Journal of the American Academy of Dermatology

2021

  1. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data

    Blood Advances, Vol. 5, pp. 5098-5106

  2. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

    European Journal of Cancer, Vol. 148, pp. 411-421

  3. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

    British Journal of Dermatology, Vol. 184, Núm. 4, pp. 722-730

2020

  1. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

    European Journal of Cancer, Vol. 133, pp. 120-130

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

  2. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

    Annals of Oncology, Vol. 28, Núm. 10, pp. 2517-2525

2016

  1. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome

    British Journal of Dermatology, Vol. 175, Núm. 1, pp. 80-88

2015

  1. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3766-3773

2011

  1. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

    Blood